MacroGenics Q3 2026: What the Revenue Miss Actually Signals

As seen on the 24/7 Wall St. homepage on November 12, 2026.

MGNX MacroGenics
Q3 2026
EPS
-$0.32
est -$0.13 -151.6%
Revenue
$19M
est $39M -52.4%

The revenue miss is lumpy partner math: last year's quarter carried a $50 million Sanofi milestone, this one only a $10 million Gilead option payment. What matters more is the $287.7 million cash pile against a $146 million market cap, funding operations through 2028 and into ADC readouts for MGC028 and MGC026 in 2027.

Continue ReadingShow less

MacroGenics reported Q3 2026 revenue of $18.67 million, missing the consensus estimate of $39.18 million by 52%. The EPS loss of $0.32 also missed expectations for a loss of $0.13. The driver is straightforward: the year-ago quarter included a $50 million milestone payment from Sanofi tied to the Provention asset purchase, while this quarter's collaboration line held only a $10 million option payment from Gilead Sciences on a preclinical bispecific program.

The year-over-year revenue decline of 74% is therefore largely a function of lumpy partner math. Royalty revenue from ZYNYZ rose by $5.3 million versus the prior year, and research and development spending came down as work on lorigerlimab, vobramitamab duocarmazine, and certain preclinical programs wound down or transitioned.

The most consequential number in the report is not on the income statement at all. Cash and marketable securities stood at $287.68 million as of September 30, 2026, a figure that management says, combined with anticipated partner payments, funds operations through 2028. With a market cap of $146 million at the time of filing, the company is trading at a meaningful discount to its cash on hand alone, a dynamic that investors in small-cap biotech tend to watch closely.

Sponsored

That runway is meant to carry MacroGenics to a cluster of clinical catalysts in 2027. The company plans to initiate a randomized two-dose-level evaluation of its ADAM9 antibody-drug conjugate MGC028 by year-end 2026, with an interim update expected in the first half of 2027. Enrollment in the 40-patient MGC026 cohort in head and neck cancer is also targeted for completion by year-end, with updated data due mid-2027, alongside first-half 2027 results from the lorigerlimab gynecologic cancer cohort.

One additional item worth noting: the GAAP EPS figure includes $0.02 per diluted share of net income from discontinued operations related to the sale of the company's contract manufacturing business to Bora, which also generated $119.6 million in cash during the quarter. The loss from continuing operations alone was $0.34 per diluted share. CEO Eric Risser characterized the period as one of meaningful strategic progress, citing approximately $290 million in non-dilutive capital raised over the prior 12 months.

Mentioned: MGNX